DOMH vs. IMNN, COSM, ERNA, CHRO, CHEK, TRIB, AKTX, BIMI, COEP, and PETV
Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Imunon (IMNN), Cosmos Health (COSM), Eterna Therapeutics (ERNA), Chromocell Therapeutics (CHRO), Check-Cap (CHEK), Trinity Biotech (TRIB), Akari Therapeutics (AKTX), BIMI (BIMI), Coeptis Therapeutics (COEP), and PetVivo (PETV). These companies are all part of the "medical" sector.
Imunon (NASDAQ:IMNN) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
In the previous week, Imunon had 6 more articles in the media than Dominari. MarketBeat recorded 6 mentions for Imunon and 0 mentions for Dominari. Dominari's average media sentiment score of 0.12 beat Imunon's score of 0.00 indicating that Imunon is being referred to more favorably in the media.
4.5% of Imunon shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 5.0% of Imunon shares are owned by company insiders. Comparatively, 9.7% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Imunon has a net margin of 0.00% compared to Imunon's net margin of -721.11%. Imunon's return on equity of -38.40% beat Dominari's return on equity.
Imunon has higher earnings, but lower revenue than Dominari. Imunon is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Imunon currently has a consensus price target of $12.00, suggesting a potential upside of 727.59%. Given Dominari's higher possible upside, research analysts plainly believe Imunon is more favorable than Dominari.
Imunon has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, Dominari has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Imunon received 9 more outperform votes than Dominari when rated by MarketBeat users.
Summary
Imunon beats Dominari on 10 of the 16 factors compared between the two stocks.
Get Dominari News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dominari Competitors List
Related Companies and Tools
